Details for: NUP98
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 27.89rCSI 33.41%PRS 42.53
-
CSI 14.31rCSI 17.17%PRS 24.48
-
CSI 12.75rCSI 19.47%PRS 25.35
-
CSI 12.13rCSI 11.14%PRS 30.02
-
CSI 8.51rCSI 10.59%PRS 26.95
-
CSI 7.74rCSI 12.75%PRS 29.65
-
CSI 7.23rCSI 26.01%PRS 14.39
-
CSI 6.96rCSI 16.91%PRS 14.91
-
CSI 6.39rCSI 7.5%PRS 28.85
-
CSI 6.34rCSI 4.21%PRS 29.79
-
CSI 6.27rCSI 10.09%PRS 19.31
-
CSI 6.17rCSI 8.57%PRS 25.48
-
CSI 5.59rCSI 12.79%PRS 24.67
-
CSI 5.51rCSI 10.94%PRS 26.08
-
CSI 5.36rCSI 6.67%PRS 34.61
-
CSI 5.27rCSI 13.68%PRS 31.3
-
CSI 5.26rCSI 23.13%PRS 22.78
-
CSI 5rCSI 3.79%PRS 34.45
-
CSI 4.98rCSI 3.84%PRS 23.67
-
CSI 4.81rCSI 13.92%PRS 48.41
-
CSI 4.8rCSI 3.59%PRS 38.87
-
CSI 4.78rCSI 6.92%PRS 37.74
-
CSI 4.6rCSI 14.16%PRS 36.32
-
CSI 4.4rCSI 25.93%PRS 15.98
-
CSI 4.3rCSI 12.45%PRS 19.69
-
CSI 4.15rCSI 6.26%PRS 25.84
-
CSI 4.12rCSI 10.87%PRS 30.01
-
CSI 3.92rCSI 10.97%PRS 38.39
-
CSI 3.88rCSI 9.27%PRS 36.47
-
CSI 3.84rCSI 11.06%PRS 43.78
-
CSI 3.81rCSI 2.65%PRS 35.33
-
CSI 3.66rCSI 8.36%PRS 21.54
-
CSI 3.63rCSI 10.32%PRS 27.52
-
CSI 3.6rCSI 4.99%PRS 33.58
-
CSI 3.57rCSI 3.1%PRS 31.8
-
CSI 3.51rCSI 20.25%PRS 30.53
-
CSI 3.48rCSI 19.64%PRS 15.22
-
CSI 3.45rCSI 2.48%PRS 34.63
-
CSI 3.38rCSI 7.59%PRS 15.82
-
CSI 3.31rCSI 2.91%PRS 29.05
-
CSI 3.3rCSI 3.37%PRS 35.66
-
CSI 3.28rCSI 7.23%PRS 28.84
-
CSI 3.19rCSI 8.25%PRS 58.51
-
CSI 3.16rCSI 5.57%PRS 14.95
-
CSI 3.12rCSI 2.77%PRS 25.51
-
CSI 3.08rCSI 3.19%PRS 29.78
-
CSI 3.06rCSI 4.7%PRS 30.3
-
CSI 3.01rCSI 9.41%PRS 17.41
-
CSI 3rCSI 4.01%PRS 27.36
-
CSI 2.89rCSI 15.19%PRS 38.8
-
CSI 2.89rCSI 3.1%PRS 23.24
-
CSI 2.82rCSI 2.15%PRS 33.4
-
CSI 2.81rCSI 6.6%PRS 35.03
-
CSI 2.8rCSI 4.94%PRS 24.57
-
CSI 2.79rCSI 13.06%PRS 46.53
-
CSI 2.74rCSI 66.11%PRS 14.89
-
CSI 2.71rCSI 6.06%PRS 29.63
-
CSI 2.68rCSI 6.2%PRS 20.37
-
CSI 2.68rCSI 64.07%PRS 13.98
-
CSI 2.57rCSI 2.97%PRS 21.85
-
CSI 2.46rCSI 4.61%PRS 18.37
-
CSI 2.44rCSI 9.84%PRS 23.44
-
CSI 2.42rCSI 9.06%PRS 21.18
-
CSI 2.41rCSI 4.6%PRS 39.2
-
CSI 2.38rCSI 9.28%PRS 40.93
-
CSI 2.37rCSI 2.95%PRS 14.27
-
CSI 2.36rCSI 1.64%PRS 30.44
-
CSI 2.36rCSI 2.32%PRS 27.01
-
CSI 2.32rCSI 4.82%PRS 24.95
-
CSI 2.27rCSI 2.66%PRS 35.46
-
CSI 2.26rCSI 6.08%PRS 32.49
-
CSI 2.24rCSI 2.34%PRS 61.16
-
CSI 2.21rCSI 5.61%PRS 19.24
-
CSI 2.19rCSI 1.78%PRS 26.35
-
CSI 2.18rCSI 3.74%PRS 33.8
-
CSI 2.18rCSI 4.83%PRS 23.3
-
CSI 2.15rCSI 7.21%PRS 18.2
-
CSI 2.15rCSI 1.27%PRS 35.48
-
CSI 2.14rCSI 1.78%PRS 23.98
-
CSI 2.14rCSI 5.88%PRS 40.16
-
CSI 2.13rCSI 1.65%PRS 36.96
-
CSI 2.05rCSI 4.08%PRS 41.24
-
CSI 2.04rCSI 2.13%PRS 25.85
-
CSI 2.03rCSI 9.73%PRS 29.85
-
CSI 2.02rCSI 3.61%PRS 23.38
-
CSI 2.01rCSI 2.49%PRS 22.25
-
CSI 2rCSI 6.52%PRS 29.8
-
CSI 1.99rCSI 1.84%PRS 44.07
-
CSI 1.97rCSI 3.22%PRS 19.47
-
CSI 1.96rCSI 1.65%PRS 29.79
-
CSI 1.9rCSI 1.67%PRS 33.19
-
CSI 1.89rCSI 1.27%PRS 31.37
-
CSI 1.88rCSI 3.77%PRS 18.7
-
CSI 1.86rCSI 5.95%PRS 21.19
-
CSI 1.85rCSI 2.83%PRS 32.55
-
CSI 1.85rCSI 1.37%PRS 21.65
-
CSI 1.84rCSI 2.02%PRS 28.16
-
CSI 1.81rCSI 4.37%PRS 39.3
-
CSI 1.81rCSI 2.57%PRS 34.81
-
CSI 1.81rCSI 2.68%PRS 28.68
-
CSI 0.1rCSI 1.5%PRS 30.8%
-
CSI 0.2rCSI 1.0%PRS 36.6%
-
CSI 0.2rCSI 4.0%PRS 22.1%
-
CSI 0.3rCSI 0.5%PRS 38.1%
-
CSI 0.3rCSI 2.3%PRS 24.1%
-
CSI 0.3rCSI 3.1%PRS 46.0%
-
CSI 0.3rCSI 1.7%PRS 36.1%
-
CSI 0.3rCSI 1.7%PRS 26.9%
-
CSI 0.4rCSI 4.9%PRS 20.1%
-
CSI 0.4rCSI 7.1%PRS 20.9%
-
CSI 0.4rCSI 0.8%PRS 25.7%
-
CSI 0.4rCSI 5.9%PRS 24.8%
-
CSI 0.4rCSI 0.8%PRS 32.1%
-
CSI 0.4rCSI 1.9%PRS 24.5%
-
CSI 0.5rCSI 2.4%PRS 47.3%
-
CSI 0.5rCSI 1.0%PRS 25.9%
-
CSI 0.5rCSI 1.7%PRS 25.9%
-
CSI 0.5rCSI 4.0%PRS 15.9%
-
CSI 0.5rCSI 2.5%PRS 48.7%
-
CSI 0.6rCSI 0.7%PRS 18.7%
-
CSI 0.6rCSI 2.4%PRS 41.2%
-
CSI 0.6rCSI 4.6%PRS 44.4%
-
CSI 0.6rCSI 1.6%PRS 55.8%
-
CSI 0.6rCSI 4.0%PRS 20.0%
-
CSI 0.6rCSI 2.1%PRS 17.2%
-
CSI 0.6rCSI 0.9%PRS 27.7%
-
CSI 0.7rCSI 2.8%PRS 44.5%
-
CSI 0.7rCSI 1.8%PRS 23.5%
-
CSI 0.7rCSI 1.6%PRS 30.7%
-
CSI 0.7rCSI 3.8%PRS 53.4%
-
CSI 0.7rCSI 1.1%PRS 32.4%
-
CSI 0.7rCSI 1.4%PRS 54.1%
-
CSI 0.7rCSI 4.0%PRS 55.9%
-
CSI 0.7rCSI 1.8%PRS 23.5%
-
CSI 0.7rCSI 1.6%PRS 18.1%
-
CSI 0.8rCSI 2.0%PRS 23.3%
-
CSI 0.8rCSI 2.2%PRS 37.7%
-
CSI 0.8rCSI 0.8%PRS 44.1%
-
CSI 0.8rCSI 1.4%PRS 32.3%
-
CSI 0.8rCSI 3.1%PRS 23.5%
-
CSI 0.8rCSI 5.4%PRS 49.4%
-
CSI 0.9rCSI 5.4%PRS 52.4%
-
CSI 0.9rCSI 1.0%PRS 30.4%
-
CSI 0.9rCSI 1.5%PRS 20.9%
-
CSI 0.9rCSI 0.8%PRS 28.3%
-
CSI 0.9rCSI 2.4%PRS 20.9%
-
CSI 0.9rCSI 4.5%PRS 33.8%
-
CSI 1.0rCSI 4.2%PRS 55.3%
-
CSI 1.0rCSI 1.4%PRS 23.2%
-
CSI 1.0rCSI 2.0%PRS 24.0%
-
CSI 1.0rCSI 2.1%PRS 47.4%
-
CSI 1.0rCSI 2.9%PRS 42.5%
-
CSI 1.0rCSI 1.5%PRS 26.8%
-
CSI 1.0rCSI 3.9%PRS 15.8%
-
CSI 1.1rCSI 0.8%PRS 41.3%
-
CSI 1.1rCSI 2.8%PRS 46.7%
-
CSI 1.1rCSI 1.4%PRS 29.1%
-
CSI 1.1rCSI 1.5%PRS 19.7%
-
CSI 1.1rCSI 2.1%PRS 61.2%
-
CSI 1.1rCSI 0.8%PRS 27.0%
-
CSI 1.1rCSI 2.1%PRS 50.1%
-
CSI 1.1rCSI 1.8%PRS 36.2%
-
CSI 1.1rCSI 2.7%PRS 36.0%
-
CSI 1.2rCSI 3.7%PRS 29.7%
-
CSI 1.2rCSI 0.9%PRS 43.9%
-
CSI 1.2rCSI 1.5%PRS 15.9%
-
CSI 1.2rCSI 1.9%PRS 16.6%
-
CSI 1.3rCSI 1.5%PRS 15.0%
-
CSI 1.3rCSI 2.8%PRS 33.3%
-
CSI 1.3rCSI 2.3%PRS 19.5%
-
CSI 1.3rCSI 2.3%PRS 21.5%
-
CSI 1.3rCSI 2.2%PRS 19.3%
-
CSI 1.3rCSI 1.6%PRS 42.8%
-
CSI 1.3rCSI 3.5%PRS 23.7%
-
CSI 1.3rCSI 5.2%PRS 46.3%
-
CSI 1.3rCSI 2.7%PRS 13.8%
-
CSI 1.3rCSI 6.4%PRS 21.4%
-
CSI 1.3rCSI 1.7%PRS 29.0%
-
CSI 1.3rCSI 1.4%PRS 26.8%
-
CSI 1.3rCSI 3.2%PRS 28.1%
-
CSI 1.4rCSI 7.5%PRS 42.1%
-
CSI 1.4rCSI 2.1%PRS 28.8%
-
CSI 1.4rCSI 3.5%PRS 30.9%
-
CSI 1.4rCSI 1.5%PRS 23.6%
-
CSI 1.4rCSI 1.1%PRS 25.4%
-
CSI 1.4rCSI 1.4%PRS 59.4%
-
CSI 1.4rCSI 2.2%PRS 21.5%
-
CSI 1.4rCSI 1.3%PRS 23.0%
-
CSI 1.4rCSI 1.8%PRS 24.2%
-
CSI 1.4rCSI 3.2%PRS 32.4%
-
CSI 1.4rCSI 1.3%PRS 37.9%
-
CSI 1.4rCSI 2.0%PRS 24.6%
-
CSI 1.5rCSI 1.6%PRS 39.6%
-
CSI 1.5rCSI 2.3%PRS 27.6%
-
CSI 1.5rCSI 1.4%PRS 26.4%
-
CSI 1.5rCSI 3.1%PRS 35.6%
-
CSI 1.5rCSI 1.5%PRS 18.7%
-
CSI 1.6rCSI 7.8%PRS 33.3%
-
CSI 1.6rCSI 1.1%PRS 26.9%
-
CSI 1.6rCSI 2.4%PRS 23.7%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 3200082497
Symbol: NUP98_HUMAN
Name: Nuclear pore complex protein Nup98
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 8563754
Title: The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9.
PubMed ID: 8563754
DOI: 10.1038/ng0296-159
PubMed ID: 10087256
Title: A conserved biogenesis pathway for nucleoporins: proteolytic processing of a 186-kilodalton precursor generates Nup98 and the novel nucleoporin, Nup96.
PubMed ID: 10087256
PubMed ID: 16554811
Title: Human chromosome 11 DNA sequence and analysis including novel gene identification.
PubMed ID: 16554811
DOI: 10.1038/nature04632
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 17974005
Title: The full-ORF clone resource of the German cDNA consortium.
PubMed ID: 17974005
PubMed ID: 10556215
Title: The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion.
PubMed ID: 10556215
PubMed ID: 10209021
Title: RAE1 is a shuttling mRNA export factor that binds to a GLEBS-like NUP98 motif at the nuclear pore complex through multiple domains.
PubMed ID: 10209021
PubMed ID: 11106761
Title: Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98.
PubMed ID: 11106761
PubMed ID: 11493482
Title: A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia.
PubMed ID: 11493482
PubMed ID: 11684705
Title: Novel vertebrate nucleoporins Nup133 and Nup160 play a role in mRNA export.
PubMed ID: 11684705
PubMed ID: 11986249
Title: NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15).
PubMed ID: 11986249
PubMed ID: 11839768
Title: Tpr is localized within the nuclear basket of the pore complex and has a role in nuclear protein export.
PubMed ID: 11839768
PubMed ID: 12802065
Title: Direct interaction with nup153 mediates binding of Tpr to the periphery of the nuclear pore complex.
PubMed ID: 12802065
PubMed ID: 15229283
Title: Nucleoporins as components of the nuclear pore complex core structure and Tpr as the architectural element of the nuclear basket.
PubMed ID: 15229283
PubMed ID: 16028218
Title: Characterization of 6q abnormalities in childhood acute myeloid leukemia and identification of a novel t(6;11)(q24.1;p15.5) resulting in a NUP98-C6orf80 fusion in a case of acute megakaryoblastic leukemia.
PubMed ID: 16028218
DOI: 10.1002/gcc.20233
PubMed ID: 15725483
Title: t(9;11)(p22;p15) with NUP98-LEDGF fusion gene in pediatric acute myeloid leukemia.
PubMed ID: 15725483
PubMed ID: 17081983
Title: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
PubMed ID: 17081983
PubMed ID: 16467868
Title: NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogenetique Hematologique.
PubMed ID: 16467868
PubMed ID: 16964243
Title: A probability-based approach for high-throughput protein phosphorylation analysis and site localization.
PubMed ID: 16964243
DOI: 10.1038/nbt1240
PubMed ID: 17287853
Title: A novel NUP98-PHF23 fusion resulting from a cryptic translocation t(11;17)(p15;p13) in acute myeloid leukemia.
PubMed ID: 17287853
PubMed ID: 18220336
Title: Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.
PubMed ID: 18220336
DOI: 10.1021/pr0705441
PubMed ID: 18691976
Title: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
PubMed ID: 18691976
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 18318008
Title: Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography.
PubMed ID: 18318008
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19690332
Title: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
PubMed ID: 19690332
PubMed ID: 19608861
Title: Lysine acetylation targets protein complexes and co-regulates major cellular functions.
PubMed ID: 19608861
PubMed ID: 20407419
Title: Protein Tpr is required for establishing nuclear pore-associated zones of heterochromatin exclusion.
PubMed ID: 20407419
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 21406692
Title: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
PubMed ID: 21406692
PubMed ID: 22058212
Title: Functional analysis of the NUP98-CCDC28A fusion protein.
PubMed ID: 22058212
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 23523133
Title: Nup153 and Nup98 bind the HIV-1 core and contribute to the early steps of HIV-1 replication.
PubMed ID: 23523133
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 25944712
Title: N-terminome analysis of the human mitochondrial proteome.
PubMed ID: 25944712
PubMed ID: 28221134
Title: Human Nup98 regulates the localization and activity of DExH/D-box helicase DHX9.
PubMed ID: 28221134
DOI: 10.7554/elife.18825
PubMed ID: 28112733
Title: Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.
PubMed ID: 28112733
DOI: 10.1038/nsmb.3366
PubMed ID: 30543681
Title: Biallelic mutations in nucleoporin NUP88 cause lethal fetal akinesia deformation sequence.
PubMed ID: 30543681
PubMed ID: 33097660
Title: SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling.
PubMed ID: 33097660
PubMed ID: 33360543
Title: Overexpression of SARS-CoV-2 protein ORF6 dislocates RAE1 and NUP98 from the nuclear pore complex.
PubMed ID: 33360543
PubMed ID: 33849972
Title: SARS-CoV-2 ORF6 Disrupts Bidirectional Nucleocytoplasmic Transport through Interactions with Rae1 and Nup98.
PubMed ID: 33849972
PubMed ID: 12191480
Title: The three-dimensional structure of the autoproteolytic, nuclear pore-targeting domain of the human nucleoporin Nup98.
PubMed ID: 12191480
PubMed ID: 18287282
Title: Structural constraints on autoprocessing of the human nucleoporin Nup98.
PubMed ID: 18287282
DOI: 10.1110/ps.073311808
PubMed ID: 20498086
Title: Structural and functional analysis of the interaction between the nucleoporin Nup98 and the mRNA export factor Rae1.
PubMed ID: 20498086
PubMed ID: 8563753
Title: Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia.
PubMed ID: 8563753
DOI: 10.1038/ng0296-154
PubMed ID: 10477737
Title: The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia.
PubMed ID: 10477737
PubMed ID: 10929031
Title: t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia.
PubMed ID: 10929031
PubMed ID: 16419055
Title: Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene.
PubMed ID: 16419055
DOI: 10.1002/gcc.20308
PubMed ID: 16959974
Title: The consensus coding sequences of human breast and colorectal cancers.
PubMed ID: 16959974
PubMed ID: 23531517
Title: NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern.
PubMed ID: 23531517
DOI: 10.1038/leu.2013.87
PubMed ID: 34163069
Title: Phase separation drives aberrant chromatin looping and cancer development.
PubMed ID: 34163069
Sequence Information:
- Length: 1817
- Mass: 197579
- Checksum: BC60E5456B936C79
- Sequence:
MFNKSFGTPF GGGTGGFGTT STFGQNTGFG TTSGGAFGTS AFGSSNNTGG LFGNSQTKPG GLFGTSSFSQ PATSTSTGFG FGTSTGTANT LFGTASTGTS LFSSQNNAFA QNKPTGFGNF GTSTSSGGLF GTTNTTSNPF GSTSGSLFGP SSFTAAPTGT TIKFNPPTGT DTMVKAGVST NISTKHQCIT AMKEYESKSL EELRLEDYQA NRKGPQNQVG AGTTTGLFGS SPATSSATGL FSSSTTNSGF AYGQNKTAFG TSTTGFGTNP GGLFGQQNQQ TTSLFSKPFG QATTTQNTGF SFGNTSTIGQ PSTNTMGLFG VTQASQPGGL FGTATNTSTG TAFGTGTGLF GQTNTGFGAV GSTLFGNNKL TTFGSSTTSA PSFGTTSGGL FGNKPTLTLG TNTNTSNFGF GTNTSGNSIF GSKPAPGTLG TGLGAGFGTA LGAGQASLFG NNQPKIGGPL GTGAFGAPGF NTTTATLGFG APQAPVALTD PNASAAQQAV LQQHINSLTY SPFGDSPLFR NPMSDPKKKE ERLKPTNPAA QKALTTPTHY KLTPRPATRV RPKALQTTGT AKSHLFDGLD DDEPSLANGA FMPKKSIKKL VLKNLNNSNL FSPVNRDSEN LASPSEYPEN GERFSFLSKP VDENHQQDGD EDSLVSHFYT NPIAKPIPQT PESAGNKHSN SNSVDDTIVA LNMRAALRNG LEGSSEETSF HDESLQDDRE EIENNSYHMH PAGIILTKVG YYTIPSMDDL AKITNEKGEC IVSDFTIGRK GYGSIYFEGD VNLTNLNLDD IVHIRRKEVV VYLDDNQKPP VGEGLNRKAE VTLDGVWPTD KTSRCLIKSP DRLADINYEG RLEAVSRKQG AQFKEYRPET GSWVFKVSHF SKYGLQDSDE EEEEHPSKTS TKKLKTAPLP PASQTTPLQM ALNGKPAPPP QSQSPEVEQL GRVVELDSDM VDITQEPVLD TMLEESMPED QEPVSASTHI ASSLGINPHV LQIMKASLLT DEEDVDMALD QRFSRLPSKA DTSQEICSPR LPISASHSSK TRSLVGGLLQ SKFTSGAFLS PSVSVQECRT PRAASLMNIP STSSWSVPPP LTSVFTMPSP APEVPLKTVG TRRQLGLVPR EKSVTYGKGK LLMDMALFMG RSFRVGWGPN WTLANSGEQL NGSHELENHQ IADSMEFGFL PNPVAVKPLT ESPFKVHLEK LSLRQRKPDE DMKLYQTPLE LKLKHSTVHV DELCPLIVPN LGVAVIHDYA DWVKEASGDL PEAQIVKHWS LTWTLCEALW GHLKELDSQL NEPREYIQIL ERRRAFSRWL SCTATPQIEE EVSLTQKNSP VEAVFSYLTG KRISEACSLA QQSGDHRLAL LLSQFVGSQS VRELLTMQLV DWHQLQADSF IQDERLRIFA LLAGKPVWQL SEKKQINVCS QLDWKRSLAI HLWYLLPPTA SISRALSMYE EAFQNTSDSD RYACSPLPSY LEGSGCVIAE EQNSQTPLRD VCFHLLKLYS DRHYDLNQLL EPRSITADPL DYRLSWHLWE VLRALNYTHL SAQCEGVLQA SYAGQLESEG LWEWAIFVLL HIDNSGIREK AVRELLTRHC QLLETPESWA KETFLTQKLR VPAKWIHEAK AVRAHMESDK HLEALCLFKA EHWNRCHKLI IRHLASDAII NENYDYLKGF LEDLAPPERS SLIQDWETSG LVYLDYIRVI EMLRHIQQVD CSGNDLEQLH IKVTSLCSRI EQIQCYSAKD RLAQSDMAKR VANLLRVVLS LHHPPDRTSD STPDPQRVPL RLLAPHIGRL PMPEDYAMDE LRSLTQSYLR ELAVGSL